293 Cells over-expressing human ADI1 and CD81 are permissive for serum-derived hepatitis C virus infection

Journal of Medical Virology

Volumn 81, Issue 9, 2009, Pages 1560-1568

  Cheng, Ju Chien ^a   Yeh, Yung Ju ^a   Pai, Li Mei ^b   Chang, Ming Ling ^c   Yeh, Chau Ting ^b,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cell entry; Claudin 1; Membrane type 1 matrix metalloproteinase

Indexed keywords

ACIREDUCTONE DIOXYGENASE 1; CD81 ANTIGEN; DIOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ELECTROPORATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; REPLICON; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANTIGENS, CD; CARRIER PROTEINS; CELL LINE; DIOXYGENASES; GENE DOSAGE; HEPACIVIRUS; HUMANS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HEPATITIS C VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 68949161939     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21495     Document Type: Article

References (36)

1. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
2. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76:13001-13014.
3. Brass V,Moradpour D, Blum HE. 2006.Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci 3:29-34.
4. Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MM, Ou JH. 2004. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39:81-89. (Pubitemid 38461470)
5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362. (Pubitemid 19117877)
6. Colombo M. 1999. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 19:263-269.
7. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T. 2004. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci USA 101:7270-7274. (Pubitemid 38638022)
8. Dunwell JM, Pruvis A, Khuri S. 2004. Cupins: The most functionally diverse protein superfamily? Phytochemistry 65:7-17.
9. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T,McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007. 446:801-805. (Pubitemid 46582027)
10. FriedMW,Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., HaussingerD, DiagoM, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
11. Harris HJ, FarquharMJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, Yuan F, Deng H, Hubscher SG, Han JH, Balfe P, McKeating JA. 2008. CD81 and claudin 1 coreceptor association: Role in hepatitis C virus entry. J Virol 82:5007-5020. (Pubitemid 351657061)
12. Heathcote J. 2000. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis 20:185-199. (Pubitemid 30623451)
13. Hirano W, Gotoh I, Uekita T, Seiki M. 2005. Membrane-type 1 matrix metalloproteinase cytoplasmic tail binding protein-1 (MTCBP-1) acts as an eukaryotic aci-reductone dioxygenase (ARD) in the methionine salvage pathway. Genes Cells 10:565-574. (Pubitemid 40867488)
14. Hwang DR, Lai HY, Chang ML, Hsu JT, Yeh CT. 2005. Emergence of mutation clusters in the HCV genome during sequential viral passages in Sip-L expressing cells. J Virol Methods 129:170-177.
15. Kato T, Date T,Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. (Pubitemid 37500445)
16. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. (Pubitemid 41033648)
17. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. 2005. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352:2609-2617. (Pubitemid 41007847)
18. Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S, Uematsu Y. 2002. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 304:187-196. (Pubitemid 36069162)
19. Matsuura Y, Tani H, SuzukiK,Kimura-Someya T, Suzuki R, AizakiH, Ishii K, Moriishi K, Robison CS, Whitt MA, Miyamura T. 2001. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 286:263-275. (Pubitemid 32721803)
20. Miyamori H, Takino T, Kobayashi Y, Tokai H, Itoh Y, SeikiM, Sato H. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem 2001. 276:28204-28211. (Pubitemid 37391525)
21. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941.
22. Randall G, Rice CM. 2001. Hepatitis C virus cell culture replication systems: Their potential use for the development of antiviral therapies. Curr Opin Infect Dis 14:743-747. (Pubitemid 33141197)
23. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese RR, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.2002. EMBO J 21:5017-5025.
24. Tani H, Komoda Y, Matsuo E, Suzuki K, Hamamoto I, Yamashita T, Moriishi K, Fujiyama K, Kanto T, Hayashi N, Owsianka A, Patel AH, Whitt MA, Matsuura Y. 2007. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol 81:8601-8612. (Pubitemid 47242834)
25. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G. 1992. Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis. J Hepatol 16:273-281. (Pubitemid 23013218)
26. Uekita T, Gotoh I, Kinoshita T, Itoh Y, Sato H, Shiomi T,Okada Y, Seiki M. 2004. Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the Cupin superfamily. A possible multifunctional protein acting as an invasion suppressor down-regulated in tumors. J Biol Chem 279:12734-12743. (Pubitemid 38445845)
27. van der Poel CL. 1999. Hepatitis C virus and blood transfusion: Past and present risks. J Hepatol 31:101-106.
28. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis Cvirus in tissue culture from a cloned viral genome. NatMed 11:791-796. (Pubitemid 41021213)
29. Wasley A, Alter MJ. 2000. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 20:1-16. (Pubitemid 30421405)
30. Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. 2000. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 74:10055-10062. (Pubitemid 30780814)
31. Yeh CT. 2004. Establishment of authentic HCV replication system for drug screening. J Gastroenterol Hepatol 19:S315-S317.
32. Yeh CT, Lu SC, Chu CM, Liaw YF. 1997a. Molecular cloning of a defective hepatitis C virus genome from the ascitic fluid of a patient with hepatocellular carcinoma. J Gen Virol 78:2761-2770.
33. Yeh CT, Shyu WC, Sheen IS, Chu CM, Liaw YF. 1997b. Quantitative assessment of hepatitis C virus RNA by polymerase chain reaction and a digoxigenin detection system: Comparison with branched DNA assay. J Virol Methods 65:219-226. (Pubitemid 27240503)
34. Yeh CT, Shen CH, Tai DI, Chu CM, Liaw YF. 2000. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene 19:5213-5220.
35. Yeh CT, Lai HY, Chen TC, Chu CM, Liaw YF. 2001. Identification of a hepatic factor capable of supporting hepatitis C virus replication in a nonpermissive cell line. J Virol 75:11017-11024.
36. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102: 9294-9299. (Pubitemid 40923557)